
FSGS and TR-MCD Study
Ages
Location
Compensation

FSGS and TR-MCD Trials in Phoenix
Aventiv Research is currently participating in an FSGS and TR-MCD study at our Phoenix, AZ location. Currently, there are no approved therapies in the US to specifically treat Focal Segmental Glomerulosclerosis (FSGS) or Treatment-Resistant Minimal Change Disease (TR-MCD). Advances in drug therapy are key to treating these diseases in their early stages and preventing further damage.
FSGS and TR-MCD Clinical Trial
The objective of this study is to evaluate the safety and efficacy of an investigational medication for the treatment of Focal Segmental Glomerulosclerosis (FSGS) and Treatment-Resistant Minimal Change Disease (TR-MCD). You may be eligible to participate in this study if you:
- Are between 18 and 75 years of age
- Have Focal Segmental Glomerulosclerosis (FSGS) AND Treatment-Resistant Minimal Change Disease (TR-MCD)
Ready to Volunteer?
Volunteer today to see if you qualify for our FSGS and TR-MCD study. Qualified volunteers may be compensated for time and travel.